Gilead Sciences (GILD) Receivables (2009 - 2026)
Gilead Sciences posted quarterly Receivables of $5.3 billion for Q1 2026, up 13.6% year-on-year from $4.7 billion in Q1 2025, and down 18.3% on a QoQ basis from $6.5 billion in Q4 2025.
Gilead Sciences (GILD) has 18 years of Receivables data on file, last reported at $5.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Receivables rose 13.6% year-over-year to $5.3 billion; the trailing twelve-month figure through Mar 2026 stood at $5.3 billion (up 13.6% YoY), and the FY2025 full-year result was $6.5 billion, up 38.9% from the prior year.
- Receivables for Q1 2026 stood at $5.3 billion, down from $6.5 billion in the prior quarter.
- Across five years, Receivables topped out at $6.5 billion in Q4 2025 and bottomed at $3.9 billion in Q1 2022.
- The 5-year median for Receivables is $4.9 billion (2023), against an average of $5.0 billion.
- The widest annual swing landed in 2023, when Receivables dropped 15.23%; it then jumped 38.9% in 2025.
- A 5-year view of Receivables shows it stood at $5.6 billion in 2022, then retreated by 15.23% to $4.8 billion in 2023, then retreated by 1.67% to $4.7 billion in 2024, then surged by 38.9% to $6.5 billion in 2025, then dropped by 18.3% to $5.3 billion in 2026.
- The last three Receivables figures came in at $5.3 billion (Q1 2026), $6.5 billion (Q4 2025), and $5.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 21.18 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 17.72 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 12.48 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 12.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 9.14 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 5.33 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 12.59 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 9.52 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 11.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.33 Bn |
| Dec 31, 2025 | 6.52 Bn |
| Sep 30, 2025 | 5.79 Bn |
| Jun 30, 2025 | 5.09 Bn |
| Mar 31, 2025 | 4.69 Bn |
| Dec 31, 2024 | 4.70 Bn |
| Sep 30, 2024 | 4.77 Bn |
| Jun 30, 2024 | 5.65 Bn |
| Mar 31, 2024 | 4.81 Bn |
| Dec 31, 2023 | 4.78 Bn |
| Sep 30, 2023 | 4.91 Bn |
| Jun 30, 2023 | 4.36 Bn |
| Mar 31, 2023 | 5.10 Bn |
| Dec 31, 2022 | 5.64 Bn |
| Sep 30, 2022 | 4.52 Bn |
| Jun 30, 2022 | 5.07 Bn |
| Mar 31, 2022 | 3.95 Bn |
| Dec 31, 2021 | 4.67 Bn |
| Sep 30, 2021 | 4.73 Bn |
| Jun 30, 2021 | 4.34 Bn |
| Mar 31, 2021 | 4.11 Bn |
| Dec 31, 2020 | 5.09 Bn |
| Sep 30, 2020 | 4.10 Bn |
| Jun 30, 2020 | 3.35 Bn |
| Mar 31, 2020 | 3.97 Bn |
| Dec 31, 2019 | 3.73 Bn |
| Sep 30, 2019 | 3.48 Bn |
| Jun 30, 2019 | 3.55 Bn |
| Mar 31, 2019 | 3.42 Bn |
| Dec 31, 2018 | 3.45 Bn |
| Sep 30, 2018 | 3.58 Bn |
| Jun 30, 2018 | 3.67 Bn |
| Mar 31, 2018 | 3.89 Bn |
| Dec 31, 2017 | 3.85 Bn |
| Sep 30, 2017 | 4.12 Bn |
| Jun 30, 2017 | 4.48 Bn |
| Mar 31, 2017 | 4.03 Bn |
| Dec 31, 2016 | 4.51 Bn |
| Sep 30, 2016 | 5.08 Bn |
| Jun 30, 2016 | 5.75 Bn |
| Mar 31, 2016 | 6.16 Bn |
| Dec 31, 2015 | 5.85 Bn |
| Sep 30, 2015 | 27.00 Mn |
| Jun 30, 2015 | 5.33 Bn |
| Mar 31, 2015 | 132.00 Mn |
| Dec 31, 2014 | 4.64 Bn |
| Sep 30, 2014 | 2.85 Bn |
| Jun 30, 2014 | 3.44 Bn |
| Mar 31, 2014 | 3.24 Bn |
| Dec 31, 2013 | 2.18 Bn |
| Sep 30, 2013 | 1.97 Bn |
| Jun 30, 2013 | 255.30 Mn |
| Mar 31, 2013 | 291.70 Mn |
| Dec 31, 2012 | 1.75 Bn |
| Sep 30, 2012 | 228.40 Mn |
| Jun 30, 2012 | 1.70 Bn |
| Mar 31, 2012 | 2.16 Bn |
| Dec 31, 2011 | 1.95 Bn |
| Sep 30, 2011 | 1.87 Bn |
| Jun 30, 2011 | 1.94 Bn |
| Mar 31, 2011 | 1.80 Bn |
| Dec 31, 2010 | 1.62 Bn |
| Sep 30, 2010 | 1.67 Bn |
| Jun 30, 2010 | 1.48 Bn |
| Mar 31, 2010 | 1.49 Bn |
| Dec 31, 2009 | 1.39 Bn |
| Sep 30, 2009 | 1.34 Bn |
| Jun 30, 2009 | 1.24 Bn |